Moving Forward by Looking Back: Critiques of Commercialised Mindfulness and the Future of (Commercialised) Psychedelics

Journal Paper by Patrick Elf, Amy Isham and Dario Leoni
History of Pharmacy and Pharmaceuticals, 65 (1) | October 2023

Summary

Much has been written in the academic and popular press on the positive consequences of psychedelic-induced mental states. Following the disappearance of psychedelic research from the public eye between the 1970s and early 2000s, a second wave of psychedelic research is gaining increasing interest from private sector actors looking to explore commercial opportunities. The commercialization of psychedelic substances will likely have consequences for how they are used, to what ends, and to what degree of efficacy. This paper reflects on the critiques of commercialised mindfulness and explores how they may apply to the future of commercialised psychedelics.

Mindfulness and psychedelics share several qualities, including their often spiritual origins and self-transcendent nature. However, mindfulness has already undergone a period of commercialization and represents a precedent case for imagining the possible outcomes of the commercialization of psychedelics. By considering the problems associated with separating the practice from its spiritual roots, co-optation to reinforce neoliberal principles, and alterations to administration to cut costs, the article demonstrates the tensions that arise when trying to implement practices rooted in enhancing wellbeing in societies dominated by consumer capitalism.

Further Reading